Business Context and Reporting Period
This Form 8-K Current Report was filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on May 6, 2020, reporting events occurring on April 30, 2020. The filing details the entry into a material definitive agreement for a firm commitment underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 7,500,000 shares of common stock.
- Offering Price: $1.00 per share.
- Gross Proceeds: $7.5 million.
- Net Proceeds: Approximately $6.8 million after underwriting discounts, commissions, and estimated expenses.
- Underwriting Fees: 7.5% of gross cash proceeds.
- Representative's Warrants: 375,000 warrants issued to the underwriter representative, exercisable at $1.25 per share.
- Warrant Terms: Exercisable starting October 28, 2020, for a period of four and one-half years.
- Other Expenses: Approximately $120,000 in company expenses (excluding underwriting fees) and a $100,000 reimbursement to the representative for out-of-pocket expenses.
Material Changes and Use of Proceeds
The primary material change is the increase in equity capital and the issuance of new shares and warrants. The filing does not provide comparative financial metrics (revenue, profit, cash flow, or debt levels) for the prior period as this is a transaction-specific report rather than a periodic financial statement.
The Company intends to use the net proceeds primarily for:
- Working capital, including reducing vendor payables and accrued employee expenses.
- General corporate purposes, which may include partnerships, business combinations, acquisitions, or investments in related or unrelated businesses.
Management Commentary, Risks, and Contingencies
- Lock-Up Agreements: Executive officers and directors have entered into 180-day lock-up agreements restricting the sale or transfer of their shares.
- Forward-Looking Statements: The report contains forward-looking statements regarding expected net proceeds, subject to risks and uncertainties detailed in other SEC filings.
- Legal Disclaimers: Representations and warranties in the Underwriting Agreement are for the benefit of the contracting parties and may not reflect facts applicable to investors.
Investor Verification Checklist
- Verify the final closing date of the offering (stated as May 5, 2020) and confirm the actual net proceeds received.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification obligations.
- Monitor the exercise of the Representative's Warrants (375,000 shares at $1.25) beginning October 28, 2020, for potential dilution.
- Confirm the status of the 180-day lock-up agreements for executive officers and directors.
- Check subsequent filings for updates on the specific allocation of the $6.8 million in net proceeds.